Unknown

Dataset Information

0

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.


ABSTRACT: Preoperative radiotherapy (RT) is commonly used to treat localised soft-tissue sarcomas (STS). Hypoxia is an important determinant of radioresistance. Whether antiangiogenic therapy can 'normalise' tumour vasculature, thereby improving oxygenation, remains unknown.Two cohorts were prospectively enrolled. Cohort A evaluated the implications of hypoxia in STS, using the hypoxic tracer (18)F-azomycin arabinoside (FAZA-PET). In cohort B, sunitinib was added to preoperative RT in a dose-finding phase 1b/2 design.In cohort A, 13 out of 23 tumours were hypoxic (FAZA-PET), correlating with metabolic activity (r(2)=0.85; P<0.001). Two-year progression-free (PFS) and overall (OS) survival were 61% (95% CI: 0.44-0.84) and 87% (95% CI: 0.74-1.00), respectively. Hypoxia was associated with radioresistance (P=0.012), higher local recurrence (Hazard ratio (HR): 10.2; P=0.02), PFS (HR: 8.4; P=0.02), and OS (HR: 41.4; P<0.04). In Cohort B, seven patients received sunitinib at dose level (DL): 0 (50?mg per day for 2 weeks before RT; 25?mg per day during RT) and two patients received DL: -1 (37.5?mg per day for entire period). Dose-limiting toxicities were observed in 4 out of 7 patients at DL 0 and 2 out of 2 patients at DL -1, resulting in premature study closure. Although there was no difference in PFS or OS, patients receiving sunitinib had higher local failure (HR: 8.1; P=0.004).In STS, hypoxia is associated with adverse outcomes. The combination of sunitinib with preoperative RT resulted in unacceptable toxicities, and higher local relapse rates.

SUBMITTER: Lewin J 

PROVIDER: S-EPMC4264446 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Preoperative radiotherapy (RT) is commonly used to treat localised soft-tissue sarcomas (STS). Hypoxia is an important determinant of radioresistance. Whether antiangiogenic therapy can 'normalise' tumour vasculature, thereby improving oxygenation, remains unknown.<h4>Methods</h4>Two cohorts were prospectively enrolled. Cohort A evaluated the implications of hypoxia in STS, using the hypoxic tracer (18)F-azomycin arabinoside (FAZA-PET). In cohort B, sunitinib was added to preo  ...[more]

Similar Datasets

| S-EPMC7189949 | biostudies-literature
| S-EPMC3021107 | biostudies-literature
| S-EPMC7674086 | biostudies-literature
| S-EPMC9096360 | biostudies-literature
| S-EPMC2733223 | biostudies-literature
| S-EPMC7465163 | biostudies-literature
| S-EPMC10068440 | biostudies-literature
| S-EPMC4153793 | biostudies-literature
| S-EPMC4718433 | biostudies-literature
| S-EPMC3248452 | biostudies-literature